Taiho’s CMO Dr Keer on positive REZILIENT3 data for zipalertinib combo
Taiho Oncology chief medical officer (CMO) Dr Harold Keer recently discussed with Srivani Venna the outcomes from the Phase III REZILIENT3…
All articles by Srivani Venna
Srivani Venna
-
-
Akeso begins Phase III study of cadonilimab for gastric cancer
Akeso has commenced a global Phase III clinical trial, with the enrolment of the first patient, to evaluate its bispecific antibody,…
-
Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC
Innovent Biologics has announced an expansion of its global Phase III MarsLight-11 trial evaluating IBI363, also known as TAK-928, to…
-
Milestone’s etripamil nasal spray enters Phase III trial for atrial fibrillation
Milestone Pharmaceuticals has commenced a pivotal Phase III trial of its etripamil nasal spray aimed at treating atrial fibrillation with…
-
Orum to begin Phase I trial of ORM-1153 after FDA clearance
The US Food and Drug Administration (FDA) has approved Orum Therapeutics' investigational new drug (IND) application for ORM-1153, a new…
-
DSMB approves dose escalation in PepGen’s FREEDOM2-DM1 study
PepGen has announced that an independent Data and Safety Monitoring Board (DSMB) has approved the progression to the highest dosage…
-
First patient dosed with DISP-10 in Dispatch Bio’s cancer trial
Dispatch Bio has dosed the first participant in a Phase I clinical trial aimed at evaluating the efficacy and safety…
-
J&J’s Mark Graham on advancing nipocalimab as treatment for SLE
J&J EMEA Immunology therapeutic area head Mark Graham tells Srivani Venna that based on positive data from the Phase II…
-
GSK announces positive outcomes from Phase I BEHOLD-1 trial of Mo-Rez
GSK has shared encouraging data from its Phase I BEHOLD-1 clinical trial of mocertatug rezetecan (Mo-Rez), an antibody-drug conjugate targeting…
-
BioNTech and DualityBio report positive data for trastuzumab pamirtecan
BioNTech and DualityBio reported encouraging data from a Phase II cohort of their global clinical study evaluating the efficacy of…